Worldwide Healthcare outperforms amid positive Trump effect

Sean Farrell WebFG News | 23 Nov, 2017 13:27 | | |

drugs pharmaceuticals biotech healthcare btg
  • 2,522.00
  • 0.12%3.00
  • Max: 2,544.00
  • Min: 2,509.00
  • Volume: 67,466
  • MM 200 : n/a
17:16 12/12/17
  • 20,073.02
  • 0.04%8.40
  • Max: 20,083.09
  • Min: 20,003.39
  • Volume: 0
  • MM 200 : n/a
17:25 12/12/17
  • 9,557.66
  • 0.15%14.40
  • Max: 9,562.02
  • Min: 9,541.72
  • Volume: 0
  • MM 200 : n/a
17:20 12/12/17
  • 4,167.58
  • 0.53%21.93
  • Max: 4,167.95
  • Min: 4,143.15
  • Volume: 0
  • MM 200 : n/a
17:20 12/12/17
  • 4,114.09
  • 0.53%21.50
  • Max: 4,114.10
  • Min: 4,090.46
  • Volume: 0
  • MM 200 : n/a
17:30 12/12/17
  • 0.00
  • 0.00%0.00
  • Max: n/a
  • Min: n/a
  • Volume: n/a
  • MM 200 : n/a
17:17 25/09/06

Worldwide Healthcare Trust said it outperformed its investment benchmark in the first six months of the year and that perceptions of healthcare stocks had improved under the presidency of Donald Trump.

The investor in global health companies said its net asset value total return was 7.4% in the six months to the end of September compared with a 2.6% return posted by the MSCI World Health Care Index.

The company's share price rose 10.8% in the same period and is trading consistently above the company's net asset value per share.

Strong performers in Worldwide's portfolio included Puma Biotechnology, whose main product treats early-stage breast cancer; BeiGene, whose lead drug targets blood cancers; and Intuitive Surgical, which develops robotic systems for surgical procedures.

The company said Donald Trump's election had eased market fears of a big shakeup of US drug prices "despite the odd tweet to the contrary from constantly combative president Trump". The administration's tax plans could also allow big drug companies such as Pfizer to repatriate cash held overseas, which would "almost assuredly stimulate an M&A frenzy", Worldwide said.

The new head of the US Food and Drug Administration, Scott Gottlieb, wants to speed up drug approvals and is "very aligned with the drug industry's best interests", the company added.

Martin Smith, Worldwide's chairman, said: "The company’s net asset value per share and the share price outperformed the company’s benchmark over the period and […] following last year’s strong performance, the current financial year has begun on a similarly positive note.

"Our portfolio manager believes that investors are now focusing more on the sector’s strong fundamentals rather than political uncertainty, with factors such as strong revenue generation, continued high levels of innovation, a more benign approval environment at the FDA and expected increased merger and acquisition activity expected to be key drivers."

More news

18:07 Results round-up

Industrial equipment rental firm Ashtead said half year earnings were boosted by clean-up efforts after hurricanes Harvey, Irma and Maria and the weak pound as it posted a 16% rise in pre-tax profits to £493.1m.

18:02 Europe close: Technology and M&A power gains in shares

Stocks on the Continent gained ground on Tuesday paced by Technology issues, even as traders waited on the US central bank's policy announcement the next day.

17:53 London close: Forties failure lifts FTSE as inflation spikes

London stocks extended their gains on Tuesday as supply disruptions boosted the energy sector and investors mulled higher than expected UK inflation figures.

17:33 US open: Boeing, 3M push Dow Industrials to fresh record-high

Wall Street's main indices are again heading higher on Tuesday as the Federal Reserve kicks off its two-day rate-setting meeting and several positive updates from corporate heavyweights such as Boeing and 3M.

17:34 EasyJet acquisition of Air Berlin assets approved by European Commission

UK budget airline easyJet cleared a major regulatory hurdle on Tuesday as its proposed acquisition of airport slots and aircraft from Air Berlin was approved by the European Commission.

17:49 Facebook to overhaul its tax structure worldwide

Facebook will move its global tax and revenue base from Ireland and begin booking advertising locally in every country where it operates.

16:51 GSK given green light for Churg-Strauss syndrome treatment

GlaxoSmithKline has been given approval by the US drug regulator for a first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.

16:44 Trump accuses Democrats of plot after sexual harassment claims

US President Donald Trump has claimed Democrats are behind a series of sexual harassment claims made against him this week.

16:41 Trump vows to send American astronauts to the moon

Donald Trump, the President of the United states signed the Space Policy Directive 1 to send astronauts to the moon again and to Mars for the first time in history.

16:33 Goldman Sachs keeps Barclays and Lloyds at 'sell'

Goldman Sachs reiterated its 'sell' recommendation on shares of Lloyds and Barclays, placing both stocks on its list of 'UK Sell Ideas' for 2018.